Group 1 - The core viewpoint of the news is that Guangshentang's stock has shown significant volatility, with a year-to-date increase of 173.77%, but recent trends indicate a decline over the past 20 and 60 days [1] - As of December 24, Guangshentang's stock price was 89.44 yuan per share, with a market capitalization of 14.245 billion yuan [1] - The company has seen a net inflow of main funds amounting to 471,200 yuan, with significant buying activity from large orders [1] Group 2 - As of September 30, the number of shareholders for Guangshentang increased by 125.95% to 45,800, while the average number of circulating shares per person decreased by 55.74% to 2,985 shares [2] - For the period from January to September 2025, Guangshentang reported an operating income of 316 million yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million yuan, down 57.96% year-on-year [2] - Since its A-share listing, Guangshentang has distributed a total of 84.6485 million yuan in dividends, with no dividends paid in the last three years [3]

Market Performance - The chemical pharmaceutical sector increased by 1.95% on December 19, with XinNuoWei leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Top Gainers in Chemical Pharmaceutical Sector - XinNuoWei (300765) closed at 34.69, up 11.44%, with a trading volume of 311,700 shares and a transaction value of 1.069 billion [1] - KangYi Pharmaceutical (300086) closed at 11.02, up 11.43%, with a trading volume of 965,500 shares and a transaction value of 1.018 billion [1] - MuNanHai Pharmaceutical (000566) closed at 7.24, up 10.03%, with a trading volume of 1,325,900 shares and a transaction value of 914 million [1] Market Capital Flow - The chemical pharmaceutical sector saw a net inflow of 68.1822 million from institutional investors, while retail investors contributed a net inflow of 31.3 million [2] - The sector experienced a net outflow of 381 million from speculative funds [2] Individual Stock Capital Flow - ST Renfu (600079) had a net inflow of 92.7508 million from institutional investors, while it faced a net outflow of 26.4283 million from speculative funds [3] - GuangShengTang (300436) recorded a net inflow of 49.2520 million from institutional investors, with a net outflow of 17.4322 million from speculative funds [3] - KangZhi Pharmaceutical (300086) had a net inflow of 28.1873 million from institutional investors, while it faced a net outflow of 3.1280 million from retail investors [3]

12月19日，广生堂涨5.02%，截至发稿，报90.63元/股，成交2.48亿元，换手率2.05%，总市值144.34亿 元。 责任编辑：小浪快报 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模1375.12万。今年以来收益11.87%， 同类排名5281/8098；近一年收益6.25%，同类排名6196/8067；成立以来亏损54.1%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 截至发稿，马毅累计任职时间11年278天，现任基金资产总规模27.18亿元，任职期间最佳基金回报 42.13%， 任职期间最差基金回报-5.55%。 麦健沛累计任职时间222天，现任基金资产总规模2.31亿元，任职期间最佳基金回报20.94%， 任职期间 最差基金回报-5.55%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号 ...

广生堂（300436.SZ）12月3日在投资者互动平台表示，尊敬的投资者，您好！GST-HG141的III期临床试 验是一项48周治疗的随机双盲研究，是公司创新药研发管线的重点项目，正按计划全力推进。为确保数 据的完整性，公司目前暂未安排该试验中期揭盲分析计划。公司将持续高效推进试验进程并及时披露创 新药重大进展，感谢您的关注和支持！ （记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：请问广生堂141三期临床会不会出中期数据？如果会的 话大概在什么时候出？ ...

Core Viewpoint - Guangshentang experienced a decline of 5.01% on December 2, with a stock price of 94.54 CNY per share and a total market capitalization of 15.057 billion CNY [1] Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015 [1] - The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications and 1.46% from other supplementary products [1] Fund Holdings - Jin Xin Fund has one fund heavily invested in Guangshentang, specifically the Jin Xin Value Selection Mixed A (005117), which held 11,000 shares, accounting for 3.65% of the fund's net value, ranking as the eighth largest holding [2] - The fund has experienced a floating loss of approximately 54,900 CNY today [2] Fund Performance - Jin Xin Value Selection Mixed A (005117) was established on September 1, 2017, with a current scale of 13.4048 million CNY [2] - Year-to-date return is 52.18%, ranking 741 out of 8122 in its category; the one-year return is 47.38%, ranking 869 out of 8056; and since inception, the return is 70.76% [2] Fund Manager Information - The fund managers are Liu Shang and Tan Zhiming, with Liu having a tenure of 102 days and a total fund size of 109 million CNY, while Tan has a tenure of 237 days with a total fund size of 141 million CNY [3] - Liu's best and worst fund returns during his tenure are -7.2% and -14.03%, respectively, while Tan's best and worst returns are 33.16% and -2.98% [3]

关于选举第五届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章 程指引》《关于新＜公司法＞配套制度规则实施相关过渡期安排》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》（等有关法律、法规和规范性文件的规定，结合公司 实际情况，公司于 2025 年 11 月 21 日召开了 2025 年第三次临时股东大会，审议 通过了《关于修订＜公司章程＞的议案》，根据修订后的《福建广生堂药业股份 有限公司章程》（以下简称"《公司章程》"），董事会由 9 名董事组成，设董 事长 1 人，独立董事 3 人，职工代表董事 1 人。 公司于 2025 年 11 月 21 日召开了职工代表大会，经与会职工代表认真讨论， 一致同意选举欧阳昭权先生（简历详见附件）为公司第五届董事会职工代表董事， 与其他现任董事共同组成公司第五届董事会，任期自本次职工代表大会选举通过 之日起至第五届董事会任期届满之日止。 欧阳昭权先生符合《公司法》等 ...

证券代码：300436 证券简称：广生堂 公告编号：2025076 福建广生堂药业股份有限公司 关于 2025 年第三次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 11 月 21 日（星期五）14:30 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 21 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 21 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年第三次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年十一月 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年第三次临时股东大会之法律意见书 致：福建广生堂药业股份有限公司 福建广生堂药业股份有限公司（以下简称"公司"）2025 年第三次临时股东 大会于 2025 年 11 月 21 日召开。国浩律师（上海）事务所（以下简称"本所"） 经公司聘请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律、法规及中国证券监督 ...

Group 1 - The core point of the article highlights the recent performance of Guangshentang, which saw a 5.03% increase in stock price, reaching 109.55 CNY per share, with a trading volume of 812 million CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 17.448 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares, with an estimated floating profit of approximately 3.7178 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 16.977 billion CNY, achieving a year-to-date return of 21.25% and a one-year return of 8.97% [2]

Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.82%, reaching 108.92 CNY per share, with a trading volume of 916 million CNY and a turnover rate of 6.61%, resulting in a total market capitalization of 17.347 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund ranks among Guangshentang's top shareholders. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating profit for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY. Year-to-date returns are 21.33%, ranking 4326 out of 8147 in its category, while the one-year return is 10.73%, ranking 5278 out of 8056 [2]